EGFR and melanoma: Additionally, high IGFBP2 can act as a regulator of PD-L1 via the EGFR–STAT3 pathway and is associated with shorter overall survival in melanomas (35), while it has also been shown that IGFBP2 can activate the EGFR-STAT3 pathway in glioma (21).